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858-5 Effect of Gender on the Outcome of Patients With 
Severe Heart Failure Treated With Carvedlloh Results of 
the COPERNICUS Study 
Michal P. Tendera. Andrew J. Coats, Michael B. Fowler, Hugo A. Katus, Paul Mohacsi, 
Jean L. Rouleau, Henry Krum, Ildiko Amann-Zalan, Nell H. Shusterman, Ellen B. 
Roecker, Milton Packer, for the COPERNICUS Study, Silesian School of Medicine, 
Katowice, Poland. 
Background: The results of the MERIT-HF trial suggested that women with heart failure 
(HF) respond less favorably to ~-blockade than men. To further explore this observation, 
we evaluated the effect of gender on the response to carvedilol (CRV) in the COPERNI- 
CUS trial. 
Methods: 2289 patients (1824 men, 465 women) with symptoms of CHF at rest or on 
minimal exertion and ejection fraction <25% were randomly assigned to placebo (PBO) 
or CRV for up to 29 months. Women were older than men (66 vs 63 yrs; P<0,001) and 
were more likely to have non-ischemic HF (42% vs 30%; P<0.001) but were similar in 
other baseline characteristics. 
Results: Shown below are Cox model (CRV:PBO) hazard ratios, 95% CI and interaction 
P values: 
Men Women Interaction 
P value 
All-cause mortality 0.65 (0.51-0.83) 0.65 (0.39-1.11) 0.98 
Death or any hospitalization 0.79 (0.68-0.91) 0,67 (0.51-0.89) 0.98 
Death or cardiovascular hospitalization 0.76 (0.65-0.90) 0.60 (0.43-0.84) 0.21 
Death or HF hospitalization 0.73 (0.61-0.87) 0.57 (0.40-0.81) 0.20 
Gender did not influence the frequency of adverse effects attributable to CRV (e.g., 
bradycardia). However, when compared with PBO, men treated with CRV were 11% less 
likely and women treated with CRV were 27% less likely to experience a serious adverse 
event (interaction P = 0.10). The risk of permanent withdrawal was lower with CRV than 
with PBO in both sexes (relative risk in women = 0.56 [95% CI, 0.33-0.96]; relative risk in 
men = 0.82 [95% CI, 0.65-1.05], interaction P=0.21). 
Conclusion: In COPERNICUS women with severe HF experienced similar clinical bene- 
fits and tolerated treatment with CRY as well as men. 
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858-6 Advanced Heart Failure Patients Unable to Reach ACE 
Inhibitor Targets: A High Risk Population Identified 
During Hospitalization 
Monica R. Shah. Vic Hasselblad, Lynne W. Stevenson, Wendy A. Gattis, Mihai 
Gheorghiade, Robert M. Catiff, Christopher M. O'Connor, Duke Clinical Research 
Institute, Durham, North Carolina, Brigham and Women's Hospital, Boston, 
Massachusetts. 
Background-ACE inhibitors (ACEI) are generally prescribed to patients with advanced 
heart failure (HF) in doses lower than shown effective in clinical trials. We sought to 
define the advanced HF population in which ACEI could not be titrated to target doses. 
Methods-The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbation 
of Chronic Congestive Heart Failure (OPTIME-CHF) enrolled 949 patients with NYHA 
class Ill-IV HF. Achieving target doses of ACEI was a predefined endpoint of the trial. 
Results-Patients unable to reach >50% ACEI target doses were older, had lower systolic 
blood pressure (BP), and higher creatinine. Clinical features of the patients are shown 
(Table). Advanced HF patients discharged on <50% ACEI had a significantly higher rate 
of death or hospitalization at 60 days than did patients taking >50% ACEI target doses, 
even after adjustment for age, NYHA class, ejection fraction (EF), creatinine, and systolic 
BP (odds ratio, 1.48; 95% CI, 1.04-2.10; p=0.03). Conclusions-Even after adjusting for 
clinical factors that contdbute both to low ACEI dosing and higher mortality, patients on 
<50% ACEI target doses had worse outcomes. This suggests an inability to tolerate 
>50% ACEi target doses defines a large subgroup of advanced HF patients with worse 
prognosis that may require new treatment strategies. 
Clinical Features of Patients on Low vs High Dose ACEI 
Clinical Feature (median,<50% ACEI Target Dose>50% ACEI Target Dose p value 
interquartlle range) (n=305) (n--422) 
Age, y 7t (60, 78) 61 (51, 73) 0.0001 
SBP, mmHg 114 (102, 131) 123 (110, 136) 0.0001 
Creatlnlne, mg/dL 1.4 (1.1, 1.7) 1.3 (1, 1.6) 0,007 
Death or hosp, % 39.3% 28.1% 0.002 
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1181-141 NOS3 Deficiency Is Associated With a Shi f t  Toward Pro- 
Oxidant Gene Expression In Murlne Myocardium 
Thomas P, Caooola, Brian Rah, Sarfraz A. Durrani, Amy Cemetich, Dan E. Berkowitz, 
Eric Hoffman, Joshua M Hare, NHLBI Program in Geoomic Applications--Hopgene, 
Johns Hopkins University, Baltimore, Maryland, Center for Genetic Medicine, Children's 
National Medical Center, Washington, DisL of Columbia. 
Background: Inhibition or transgenic detetion of NOS3 has adverse effects on contrac- 
tile function in vitro, and leads to hypertension and leff ventricular hypertrophy in vivo. A 
large body of data indicates that nitric oxide (NO) exerts many of its effects by interacting 
with a complex network of redox signaling pathways. Using a genomic approach, we 
tested the hypothesis that NOS3 deficiency leads to compensatory changes in the 
expression of redox genes in murine myocardium. 
Methods: Myocardial RNA was isolated from NOS3 "/" mice and their appropriate C57BI/ 
6 controls (n=3 each, age 4.0 +/- 0.5 mos.; Tdzol reagent extraction method). Within 
each group, samples were combined in equimolar amounts resulting in single NOS3 "/" 
and control RNA pools. Duplicate in vitro transcriptions were performed on each pool to 
form 2 NOS3 "/" and 2 control cRNA probes that were each hybridized with a murine 
Affymetrix MG74A chip containing ~6,000 genes and -6000 ESTs. Relative expression 
of a predefined group of oxidases, the superoxide dismutases (SOD), catalase, and 
members of the glutathione pathway were compared among the NOS3 "/" and control 
pools. Statistical significance was determined using a Monte-Carlo method. 
Results: Of the 40 genes examined, seven were under-expressed in NOS3 "/" myooar- 
dium, including mitochondrial and cytosolic SOD, glutathione transferase, and five 
nuclear-encoded subunits of cyctoohrome C oxidase (complex IV). In contrast, only 
extracallular SOD was over-expressed. 
Conclusions: These data indicate a shift in myocardial gane transcription toward a pro- 
oxidant state in the absence of NOS3. In addition to increasing ventricular afterload, 
NOS3 deficiency may promote ventricular hypertrophy by promoting oxidative stress 
within the myooardium. 
1181-142 Compensatory  Electr ical  Remode l ing  in Hearts of  
Transgenic Mice That Overexpress the Ca2+ Channel 
Alpha 1C Subunit 
Ilona Bodi, James N. Muth, Gyula Varadi, Natasha N. Petrashevskaya, Arnold Schwartz, 
University of Cincinnati, Cincinnati, Ohio. 
Background: Prolongation of the action potential duration (APD) and a reduction of the 
transient outward K + current (Ito) are thought o be hallmarks of hypertrophy. A model in 
which the c( 1 subunit of the L-voltage-dependent calcium channel is over-expressed in 
transgenic mice offers an opportunity to study this phenomenon in detail. 
Methods: We used the whole-cell patch-clamp technique, radioligand binding and retro- 
grade perfused hearts to characterize this model at the cell and organ level. 
Results: Electrophysiological analysis in ventricular myocytes isolated from transgenic 
(Tg) and nontransgsnic (Ntg) mice at 4-month of age (mild hypertrophy) demonstrated a 
slight decrease in the APD at 90% repoladzation (APD90) and an up-regulation of the L- 
type Ca2+-current and dihydropyridine binding. The changes were accompanied by a 
small increase in Ito density without altering the staady-state inactivation. No change was 
detected in the protein expression level of Kv4.3 and 4.2 up to 8-months of age. Kvl.4 
was up-regulated in Tg hearts from 8-month old mice. In cardiomyocytes from 10-12 
month old Tg mice (hypertrophied and failing) APD90 was longer compared to Ntgs; 4- 
aminopyridine evoked spontaneous triggered activity and hearts revealed a very low 
basal contractility. At -140 mV no significant change was observed between Tg and Ntg 
cells in the inwardly rectifying potassium current. The Ito up-regulation may exert a com- 
pensatory function for the high Ca 2+ induced prolongation of APD. At 10-12 months the 
Tg mice showed a slight decrease (41.4%±6.9, P<0.05, n=3) in Kv4.2 consistent with a 
decrease in Ito. 
Conclusion: This study demonstrates the complexity of ion current changes in a model 
of hypertrophy and failure, and the difficulty of using the APD as a hallmark of cardiac 
hypertrophy. The data also suggest that increased [Ca2+]i may be an important factor not 
only in triggering disease but in electrical remodeling. 
1181-143 A Novel Efficient Percutaneous Myocardial Gene 
Del ivery System 
Ronen BeerL Luis J. Guerrero, Suzanne Sullivan, Gregory Supple, Robert A. Levine, 
Roger J. Hajjar, Massachusetts General Hospital, Boston, Massachusetts. 
Manipulating gene expression in the failing heart has therapeutic promise, but up to now 
efficient and homogeneous cardiac gene delivery has required an open-chest approach. 
Critical conditions to maximize percutaneously delivered gene expression include pro- 
longing the exposure to the viral vector and enhancing its myocardial uptake across the 
end(~thelial barrier, Ultrasound-induced disruption of echo contrast microbubblas 
enhances endothelial crossing. We planned to maximize vector delivery with bubbles by 
injection into the aortic root with brief balloon occlusion above the sinuses, while prolong- 
ing diastole and vasodUating with acetylchotine (ACh). 
Methods: In 20 male rats an angioplasty balloon catheter was positioned just above the 
aortic valve via the right carotid artery. The LV was imaged in long axis view with an 
esophageal echo catheter (AcuNav). in 5 rats, the balloon was inflated and 1.5 ~g ACh 
